[go: up one dir, main page]

WO2009004873A1 - プロスタグランジン誘導体含有水性液剤 - Google Patents

プロスタグランジン誘導体含有水性液剤 Download PDF

Info

Publication number
WO2009004873A1
WO2009004873A1 PCT/JP2008/059774 JP2008059774W WO2009004873A1 WO 2009004873 A1 WO2009004873 A1 WO 2009004873A1 JP 2008059774 W JP2008059774 W JP 2008059774W WO 2009004873 A1 WO2009004873 A1 WO 2009004873A1
Authority
WO
WIPO (PCT)
Prior art keywords
aqueous liquid
liquid agent
prostaglandin derivative
containing aqueous
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/059774
Other languages
English (en)
French (fr)
Inventor
Kaori Nishizaki
Takayuki Sato
Kentaro Goto
Kuniaki Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP2009521556A priority Critical patent/JPWO2009004873A1/ja
Priority to US12/666,804 priority patent/US8044104B2/en
Priority to EP08764790A priority patent/EP2172202A4/en
Publication of WO2009004873A1 publication Critical patent/WO2009004873A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

（ａ）下記式（Ｉ） で表されるプロスタグランジン誘導体若しくはその製薬学的に許容される塩又はそれらの水和物、並びに、（ｂ）グリセリン、プロピレングリコール、ジプロピレングリコール及び１，３－ブチレングリコールの少なくとも１種の多価アルコール、を含有することを特徴とする水性液剤を提供する。
PCT/JP2008/059774 2007-06-29 2008-05-28 プロスタグランジン誘導体含有水性液剤 Ceased WO2009004873A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009521556A JPWO2009004873A1 (ja) 2007-06-29 2008-05-28 プロスタグランジン誘導体含有水性液剤
US12/666,804 US8044104B2 (en) 2007-06-29 2008-05-28 Prostaglandin derivative-containing aqueous liquid preparation
EP08764790A EP2172202A4 (en) 2007-06-29 2008-05-28 A PROSTAGLAND DERIVATIVE CONTAINING AQUEOUS LIQUID MEDIUM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-172331 2007-06-29
JP2007172331 2007-06-29

Publications (1)

Publication Number Publication Date
WO2009004873A1 true WO2009004873A1 (ja) 2009-01-08

Family

ID=40225929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/059774 Ceased WO2009004873A1 (ja) 2007-06-29 2008-05-28 プロスタグランジン誘導体含有水性液剤

Country Status (4)

Country Link
US (1) US8044104B2 (ja)
EP (1) EP2172202A4 (ja)
JP (1) JPWO2009004873A1 (ja)
WO (1) WO2009004873A1 (ja)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02282329A (ja) * 1989-04-25 1990-11-19 Green Cross Corp:The プロスタグランジン含有液状組成物
JPH05229928A (ja) * 1992-02-24 1993-09-07 Kao Corp 化粧水
WO1997030696A1 (en) * 1996-02-26 1997-08-28 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
JP2000319163A (ja) * 1999-05-07 2000-11-21 Masako Motomura 肌洗浄液、および肌払拭材
JP2003238328A (ja) * 2002-02-13 2003-08-27 Fancl Corp 低刺激性皮膚外用剤
JP2003238336A (ja) * 2002-02-13 2003-08-27 Fancl Corp 化粧料組成物
JP2003528895A (ja) * 2000-03-31 2003-09-30 ザ プロクター アンド ギャンブル カンパニー オキシミルプロスタグランジン及びヒドロキシルアミノプロスタグランジンを使用した脱毛症治療用組成物及びその治療方法
WO2004014394A1 (ja) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co.,Ltd. 止痒剤
WO2005044276A1 (ja) * 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
JP2005247842A (ja) * 2004-02-06 2005-09-15 Taisho Pharmaceut Co Ltd 乾皮症治療剤
WO2006085655A1 (ja) 2005-02-14 2006-08-17 Taisho Pharmaceutical Co., Ltd. 軟膏剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
US7254362B2 (en) * 2003-11-07 2007-08-07 Ricoh Company, Ltd. Fixing device, image forming apparatus using the fixing device, and heat insulating member

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02282329A (ja) * 1989-04-25 1990-11-19 Green Cross Corp:The プロスタグランジン含有液状組成物
JPH05229928A (ja) * 1992-02-24 1993-09-07 Kao Corp 化粧水
WO1997030696A1 (en) * 1996-02-26 1997-08-28 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
JP2000319163A (ja) * 1999-05-07 2000-11-21 Masako Motomura 肌洗浄液、および肌払拭材
JP2003528895A (ja) * 2000-03-31 2003-09-30 ザ プロクター アンド ギャンブル カンパニー オキシミルプロスタグランジン及びヒドロキシルアミノプロスタグランジンを使用した脱毛症治療用組成物及びその治療方法
JP2003238328A (ja) * 2002-02-13 2003-08-27 Fancl Corp 低刺激性皮膚外用剤
JP2003238336A (ja) * 2002-02-13 2003-08-27 Fancl Corp 化粧料組成物
WO2004014394A1 (ja) 2002-08-09 2004-02-19 Taisho Pharmaceutical Co.,Ltd. 止痒剤
WO2005044276A1 (ja) * 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
JP2005247842A (ja) * 2004-02-06 2005-09-15 Taisho Pharmaceut Co Ltd 乾皮症治療剤
WO2006085655A1 (ja) 2005-02-14 2006-08-17 Taisho Pharmaceutical Co., Ltd. 軟膏剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DRAIZE: "Appraisal of the safety of chemicals in foods, drugs and cosmetics", 1959, ASSOCIATION OF FOOD & DRUG OFFICIALS OF THE UNITED STATES, pages: 46 - 59
KAY; CALANDRA: "Interpretation of eye irritation tests", J. SOC. COSM. CHEM., vol. 13, 1962, pages 281 - 289
See also references of EP2172202A4
TAKANO N ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 471, 2003, pages 223 - 8

Also Published As

Publication number Publication date
EP2172202A1 (en) 2010-04-07
EP2172202A4 (en) 2010-06-30
JPWO2009004873A1 (ja) 2010-08-26
US20100204331A1 (en) 2010-08-12
US8044104B2 (en) 2011-10-25

Similar Documents

Publication Publication Date Title
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008005542A3 (en) Antiviral phosphinate compounds
WO2011080148A3 (en) An aqueous intravenous nanosuspension with reduced adverse effects
TW200728307A (en) Novel spirochromanone derivatives
WO2009084021A3 (en) Ophthalmic composition comprising a prostaglandin
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2008090066A3 (en) Stabilization of uv-sensitive active ingredients
WO2008083252A3 (en) Methods of use for cyclopamine analogs
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2009150137A3 (en) Pyrazine derivatives as epithelial sodium channel blockers
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2007062399A3 (en) Oncogenic ras-specific cytotoxic compound and methods of use thereof
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
WO2006113552A8 (en) Cyanoarylamines
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2007112913A3 (en) Benzimidazole derivatives
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007133481A3 (en) Method for increasing the bioavailability of benzhydryl piperazine containing compounds
GEP20125525B (en) Stable liquid pharmaceutical composition based on trazodone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08764790

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009521556

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12666804

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008764790

Country of ref document: EP